TSLP upregulation in human SSc skin and induction of overlapping profibrotic genes and intracelullar signaling with IL-13 and TGFß. Christmann RB, Mathes A, Affandi AJ, Padilla C, Nazari B, Bujor AM, Stifano G, Lafyatis R.Arthritis Rheum. 2013 Jan 17. doi: 10.1002/art.37859. [Epub ahead of print] PubMed PMID: 23335246.  Click here to view the figures associated with this publication.

Increased expression of endoplasmic reticulum stress genes in patients with limited systemic sclerosis and pulmonary arterial hypertension.  Lenna S, Farina AG, Martyanov V, Christmann RB, Wood TA, Farber HW, Scorza R, Whitfield ML, Lafyatis R, Trojanowska M.  Arthritis Rheum. 2013;65(5):1357-66.

Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. Pendergrass SA, Hayes E, Farina G, Lemaire R, Farber HW, Whitfield ML,  R.  PLoS One. 2010; 17;5:e12106.

Interferon and alternative activation of macrophage/monocytes in systemic sclerosis-associated pulmonary arterial hypertension. Christmann RB, Hayes E, Pendergrass S, Padilla C, Farina G, Whitfield M, Farber HW, Lafyatis R.  Arthritis Rheum 2011; 63:1718-1728.

The role of ER stress and the unfolded protein response in fibrosis.  Lenna S and Trojanowska M, Curr Opinion Rheum, invited review, 2012.

Molecular Signatures in Skin Associated with Clinical Improvement During Mycophenolate Treatment in Systemic Sclerosis. Hinchcliff ME, Huang CC, Wood TA, Mahoney JM, Martyanov V, Bhattacharya S, Tamaki Z, Carns M, Podlusky S, Sirajuddin A, Shah SJ, Lafyatis R, Varga J, Whitfield ML. J Invest Dermatol. 2013;In Press.  PMCID:  PMC3714324 [Available on 2014/2/1]

Interspecies Comparison of Human and Murine Scleroderma Reveals IL-13 and CCL2 as Disease Subset-Specific Targets. Greenblatt MB, Sargent JL, Farina G, Tsang K, Lafyatis R, Glimcher LH, Whitfield ML, Aliprantis AO. Am J Pathol. 2012.  PMCID:  PMC3349888

Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. Pendergrass SA, Lemaire R, Francis IP, Mahoney JM, Lafyatis R, Whitfield ML.  J Invest Dermatol. 2012 May;132(5):1363-73. doi: 10.1038/jid.2011.472. Epub 2012 Feb 9.  PMID:  22318389.  PMCID:  PMC3326181

Connective tissue disease: SSc-fibrosis takes flight with Wingless inhibition. Lafyatis R.  Nat Rev Rheumatol. 2012 Aug;8(8):441-2. doi: 10.1038/nrrheum.2012.99. Epub 2012 Jul 3. PMID:  22751566.  PMID:  22751566 [PubMed – indexed for MEDLINE]

Acid sphingomyelinase deficiency contributes to resistance of scleroderma fibroblasts to Fas-mediated apoptosis. Samuel GH, Lenna S, Bujor AM, Lafyatis R, Trojanowska M.  J Dermatol Sci. 2012 Sep;67(3):166-72. doi: 10.1016/j.jdermsci.2012.06.001. Epub 2012 Jun 26.  PMID:  22771321.  PMCID:  PMC3423203 [Available on 2013/9/1]

New insights into the mechanisms of innate immune receptor signalling in fibrosis. Lafyatis R, Farina A.  Open Rheumatol J. 2012;6:72-9. doi: 10.2174/1874312901206010072. Epub 2012 Jun 15.  PMID:  22802904.  PMCID:  PMC3396286

Toll-Like Receptor 4 Signaling Augments Transforming Growth Factor-β Responses: A Novel Mechanism for Maintaining and Amplifying Fibrosis in Scleroderma. Bhattacharyya S, Kelley K, Melichian DS, Tamaki Z, Fang F, Su Y, Feng G, Pope RM, Budinger GR, Mutlu GM, Lafyatis R, Radstake T, Feghali-Bostwick C, Varga J.  Am J Pathol. 2013 Jan;182(1):192-205. doi: 10.1016/j.ajpath.2012.09.007. Epub 2012 Nov 7.  PMID:  23141927.  PMCID:  PMC3538029 [Available on 2014/1/1]

p300 Is Elevated in Systemic Sclerosis and Its Expression Is Positively Regulated by TGF-β: Epigenetic Feed-Forward Amplification of Fibrosis. Ghosh AK, Bhattacharyya S, Lafyatis R, Farina G, Yu J, Thimmapaya B, Wei J, Varga J.  J Invest Dermatol. 2013 Jan 10. doi: 10.1038/jid.2012.479. PMID:  23303459.  PMCID:  PMC3626729 [Available on 2013/11/1]

TSLP upregulation in human SSc skin and induction of overlapping profibrotic genes and intracelullar signaling with IL-13 and TGFß.  Christmann RB, Mathes A, Affandi AJ, Padilla C, Nazari B, Bujor AM, Stifano G, Lafyatis R.  Arthritis Rheum. 2013 Jan 17. doi: 10.1002/art.37859. PMID:  23335246.

HLA-B35 and dsRNA induce endothelin-1 via activation of ATF4 in human microvascular endothelial cells. Lenna S, Chrobak I, Farina GA, Rodriguez-Pascual F, Lamas S, Lafyatis R, Scorza R, Trojanowska M.  PLoS One. 2013;8(2):e56123. doi: 10.1371/journal.pone.0056123. Epub 2013 Feb 18.  PMCID:  PMC3575387

Endothelial GATA-6 Deficiency Promotes Pulmonary Arterial Hypertension. Ghatnekar A, Chrobak I, Reese C, Stawski L, Seta F, Wirrig E, Paez-Cortez J, Markiewicz M, Asano Y, Harley R, Silver R, Feghali-Bostwick C, Trojanowska M.  Am J Pathol. 2013 Jun;182(6):2391-406. doi: 10.1016/j.ajpath.2013.02.039. Epub 2013 Apr 11.  PMCID:  PMC3668018  [Available on 2014/6/1]

Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis. Stawski L, Han R, Bujor AM, Trojanowska M.  Arthritis Res Ther. 2012 Aug 22;14(4):R194. PMCID:  PMC3580592

A role for estrogen receptor-α and estrogen receptor-β in collagen biosynthesis in mouse skin. Markiewicz M, Znoyko S, Stawski L, Ghatnekar A, Gilkeson G, Trojanowska M. J Invest Dermatol. 2013 Jan;133(1):120-7. doi: 10.1038/jid.2012.264. PMCID:  PMC3502697

The Role of TGF-β Receptors in Fibrosis. Nakerakanti S, Trojanowska M.  Open Rheumatol J. 2012;6:156-62. doi: 10.2174/1874312901206010156. Epub 2012 Jun 15.

Mediators of fibrosis. Trojanowska M.  Open Rheumatol J. 2012;6:70-1. doi: 10.2174/1874312901206010070. Epub 2012 Jun 15.  PMCID:  PMC3396054

Use of Selective Serotonin Reuptake Inhibitors and Outcomes in Pulmonary Arterial Hypertension. Sadoughi A, Roberts KE, Preston IR, Lai GP, McCollister DH, Farber HW, Hill NS.  Chest. 2013 Apr 4. doi: 10.1378/chest.12-2081. PMID:  23558791 [PubMed – in process]

Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: initial clinical experience. Esch JJ, Shah PB, Cockrill BA, Farber HW, Landzberg MJ, Mehra MR, Mullen MP, Opotowsky AR, Waxman AB, Lock JE, Marshall AC.  J Heart Lung Transplant. 2013 Apr;32(4):381-7. doi: 10.1016/j.healun.2013.01.1049. PMID:  23415728 [PubMed – in process]

Comorbid Conditions and Outcomes in Patients With Pulmonary Arterial Hypertension: A REVEAL Registry Analysis. Poms AM, Turner M, Farber HW, Meltzer LA, McGoon MD. Chest. 2013 Jan 24. doi: 10.1378/chest.11-3241. PMID:  23348820 [PubMed – in process]

Ophthalmologic diagnosis of exacerbation of idiopathic pulmonary arterial hypertension. Skondra D, Chang GC, Farber HW, Eliott D.  Arch Ophthalmol. 2012 Dec 1;130(12):1619-21. doi: 10.1001/archophthalmol.2012.1802. PMID:  23229713 [PubMed – in process]

Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY®. Kitterman N, Poms A, Miller DP, Lombardi S, Farber HW, Barst RJ.  Mayo Clin Proc. 2012 Sep;87(9):825-34. doi: 10.1016/j.mayocp.2012.05.014. Epub 2012 Aug 9.  PMCID:  PMC3498408

Validation of the 6-minute walk in patients with pulmonary arterial hypertension: trying to fit a square PEG into a round hole? Farber HW.  Circulation. 2012 Jul 17;126(3):258-60. doi: 10.1161/CIRCULATIONAHA.112.118547. PMID:  22696078 [PubMed – indexed for MEDLINE]

Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry. Frost AE, Farber HW, Barst RJ, Miller DP, Elliott CG, McGoon MD. Chest. 2013 Jan;143(1):185-95. PMID:  22661451 [PubMed – indexed for MEDLINE]